Cure My Disease

Don't miss your cure!

 Log in / Sign up

New rapid blood test aims to catch a hidden parasite

NCT ID NCT07876622

Diagnosis Sponsor: IRCCS Sacro Cuore Don Calabria di Negrar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 15, 2026 · Last updated Oct 16, 2026 · Updated 1 time

Summary

Strongyloides stercoralis is a parasite that can cause long-lasting infection, and standard lab tests often miss it. Researchers are checking whether a new rapid blood test called SsRT+ detects the infection accurately enough to meet World Health Organization standards. The study analyzes stored serum samples from people who had screening tests, comparing SsRT+ and a prototype test against existing antibody and stool tests. No patients are involved, only leftover samples from a biobank.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a new rapid diagnostic blood test called SsRT+
What this could lead to
If it works, this could give clinics a faster, simpler way to diagnose a parasitic infection that often goes undetected.
What could go wrong
The test may miss infections or give false alarms compared with standard lab methods. This study uses stored blood samples, so it cannot show how the test performs in a real clinic.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 780 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Serum from individuals who were prescribed screening tests for S. stercoralis * Written consent to the donation of the leftover sample to the local biobank Exclusion Criteria: * Unavailable/insufficient quantity of serum * Serum from individuals who received treatment with ivermectin in the previous 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Device performance are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease strongyloidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Device performance Diagnostic Strongyloides stercoralis infection

Contacts and locations

Locations

  • IRCCS Sacro Cuore Don Calabria Hospital

    Negrar, Verona, 37024, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.